AngioDynamics (ANGO) Presents At Barclays Virtual Global Healthcare Conference - Slideshow

Strategic Transformation - AngioDynamics is pursuing larger markets through active portfolio management, relying on technology and innovation to produce measurable patient outcomes[5] - The company is focusing resource development in areas that offer the best opportunities for success[6] - Portfolio transformation and strength is driven by R&D, M&A, and Clinical & Regulatory efforts, combined with top talent to drive value[7] Peripheral Atherectomy - The US addressable market for Peripheral Atherectomy is $555 million, with mechanical atherectomy accounting for 77% and laser atherectomy for 23%[19] - AngioDynamics launched the Auryon System in 2021, providing access to the peripheral atherectomy market[9] Thrombus Management - AngioDynamics is targeting a $77 million addressable market in the Right Atrium with its AngioVac system[28] - The company is planning to launch a multi-purpose mechanical aspiration device to compete in the broader DVT & PE markets, which are valued at $1.3 billion and $1.6 billion respectively[28, 33] - There are 208,000 Iliofemoral Deep Vein Thrombosis cases and 171,000 High-risk & intermediate-risk Pulmonary Embolism cases[25] Irreversible Electroporation (NanoKnife) - In 2020, there were 1,256,970 new cancer cases[40] - 38% of prostate cancer patients are ideal candidates for focal therapy[48] Financial Performance (First Half FY2021) - AngioDynamics reported revenue of $143.0 million, a 5.1% increase year-over-year[53] - Adjusted EBITDA was $9.6 million[53] - AngioVac grew 34% and NanoKnife Disposables grew 12%[55] - Auryon revenue contribution was $3.2 million[55]